Tagless LysoIP for immunoaffinity enrichment of native lysosomes from clinical samples

Daniel Saarela, Paweł Lis, Sara Gomes, Raja Nirujogi, Wentao Dong, Eshaan S. Rawat, Sophie Glendinning, Karolina Zeneviciute, Enrico Bagnoli, Rotimi Fasimoye, Cindy Lin, Kwamina Nyame, Fanni A. Boros, Friederike Zunke, Fred Lamoliatte, Sadik Elshani, Matthew Jaconelli, Judith J. M. Jans, Margriet A. Huisman, Christian PosernLena M. Westermann, Angela Schulz, Peter M. van Hasselt, Dario Alessi (Lead / Corresponding author), Monther Abu-Remaileh (Lead / Corresponding author), Esther Sammler (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

Abstract

Lysosomes are implicated in a wide spectrum of human diseases including monogenic lysosomal storage disorders (LSDs), age-associated neurodegeneration and cancer. Profiling lysosomal content using tag-based lysosomal immunoprecipitation (LysoTagIP) in cell and animal models has substantially moved the field forward, but studying lysosomal dysfunction in human patients remains challenging. Here, we report the development of the 'tagless LysoIP' method, designed to enable the rapid enrichment of lysosomes, via immunoprecipitation, using the endogenous integral lysosomal membrane protein TMEM192, directly from clinical samples and human cell lines (e.g., induced pluripotent stem cell derived neurons). Isolated lysosomes were intact and suitable for subsequent multimodal omics analyses. To validate our approach, we applied the tagless LysoIP to enrich lysosomes from peripheral blood mononuclear cells derived from fresh blood of healthy donors and patients with CLN3 disease, an autosomal recessive neurodegenerative LSD. Metabolic profiling of isolated lysosomes revealed massive accumulation of glycerophosphodiesters (GPDs) in patients' lysosomes. Interestingly, a patient with a milder phenotype and genotype displayed lower accumulation of lysosomal GPDs, consistent with their potential role as disease biomarkers. Altogether, the tagless LysoIP provides a framework to study native lysosomes from patient samples, identify disease biomarkers, and discover human-relevant disease mechanisms.
Original languageEnglish
JournalJournal of Clinical Investigation
DOIs
Publication statusE-pub ahead of print - 26 Dec 2023

Fingerprint

Dive into the research topics of 'Tagless LysoIP for immunoaffinity enrichment of native lysosomes from clinical samples'. Together they form a unique fingerprint.

Cite this